IPSC vs. CRDF, ADVM, STRO, BDTX, OPT, CHRS, KOD, ABOS, CMPX, and PSTX
Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Cardiff Oncology (CRDF), Adverum Biotechnologies (ADVM), Sutro Biopharma (STRO), Black Diamond Therapeutics (BDTX), Opthea (OPT), Coherus BioSciences (CHRS), Kodiak Sciences (KOD), Acumen Pharmaceuticals (ABOS), Compass Therapeutics (CMPX), and Poseida Therapeutics (PSTX). These companies are all part of the "biological products, except diagnostic" industry.
Century Therapeutics (NASDAQ:IPSC) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.
50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 7.6% of Century Therapeutics shares are owned by company insiders. Comparatively, 6.3% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Cardiff Oncology has lower revenue, but higher earnings than Century Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Century Therapeutics had 7 more articles in the media than Cardiff Oncology. MarketBeat recorded 12 mentions for Century Therapeutics and 5 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.14 beat Century Therapeutics' score of 0.67 indicating that Cardiff Oncology is being referred to more favorably in the news media.
Cardiff Oncology received 10 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 61.67% of users gave Cardiff Oncology an outperform vote while only 60.00% of users gave Century Therapeutics an outperform vote.
Century Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.
Century Therapeutics presently has a consensus target price of $13.60, indicating a potential upside of 357.14%. Cardiff Oncology has a consensus target price of $10.50, indicating a potential upside of 140.27%. Given Century Therapeutics' higher possible upside, equities analysts clearly believe Century Therapeutics is more favorable than Cardiff Oncology.
Century Therapeutics has a net margin of -6,115.12% compared to Cardiff Oncology's net margin of -8,492.01%. Cardiff Oncology's return on equity of -50.13% beat Century Therapeutics' return on equity.
Summary
Century Therapeutics and Cardiff Oncology tied by winning 9 of the 18 factors compared between the two stocks.
Get Century Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Century Therapeutics Competitors List
Related Companies and Tools
